We are live on ! Find out more

2,910 hedge funds and large institutions have $109B invested in Pfizer in 2024 Q3 according to their latest regulatory filings, with 191 funds opening new positions, 1,243 increasing their positions, 1,199 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more first-time investments, than exits

New positions opened: 191 | Existing positions closed: 124

27% more funds holding in top 10

Funds holding in top 10: 3342 (+9)

1% more funds holding

Funds holding: 2,8742,910 (+36)

4% more repeat investments, than reductions

Existing positions increased: 1,243 | Existing positions reduced: 1,199

4% more capital invested

Capital invested by funds: $105B → $109B (+$3.84B)

0.39% more ownership

Funds ownership: 66.08%66.47% (+0.39%)

38% less call options, than puts

Call options by funds: $2.51B | Put options by funds: $4.05B

Holders
2,910
Holders Change
+36
Holders Change %
+1.25%
% of All Funds
41.78%
Holding in Top 10
42
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+27.27%
% of All Funds
0.6%
New
191
Increased
1,243
Reduced
1,199
Closed
124
Calls
$2.51B
Puts
$4.05B
Net Calls
-$1.54B
Net Calls Change
-$268K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
1176
Bourgeon Capital Management
Connecticut
$1.71M +$219K +7,498 +15%
AA
1177
Apriem Advisors
California
$1.7M +$164K +5,626 +11%
CI
1178
Cigna Investments
Connecticut
$1.7M -$24.9K -853 -1%
FWCM
1179
Ferguson Wellman Capital Management
Oregon
$1.69M -$23.5K -804 -1%
CPSAC
1180
Chas P. Smith & Associates (CPS)
Florida
$1.69M -$250K -8,562 -13%
CMI
1181
Clare Market Investments
Texas
$1.69M +$1.42M +48,516 +495%
QCG
1182
Quadrant Capital Group
Ohio
$1.69M -$35.7K -1,224 -2%
QT
1183
Quantbot Technologies
New York
$1.69M +$1.7M +58,233 New
NLP
1184
Next Level Private
New York
$1.68M +$124K +4,234 +8%
CIA
1185
Cladis Investment Advisory
Montana
$1.68M +$35.8K +1,228 +2%
CCP
1186
Clough Capital Partners
Massachusetts
$1.68M +$1.69M +58,100 New
CFMC
1187
Curbstone Financial Management Corp
New Hampshire
$1.68M -$111K -3,814 -6%
ATPW
1188
Ashton Thomas Private Wealth
Arizona
$1.68M -$754K -25,833 -31%
RPC
1189
Rossmore Private Capital
Connecticut
$1.68M -$8.75K -300 -0.5%
CCP
1190
Clarkston Capital Partners
Michigan
$1.67M +$400K +13,700 +31%
PWA
1191
Provenance Wealth Advisors
Florida
$1.67M +$20.5K +704 +1%
SGCA
1192
Steel Grove Capital Advisors
Tennessee
$1.67M -$34.6K -1,187 -2%
BLC
1193
Brown, Lisle/Cummings
Rhode Island
$1.66M +$4.61K +158 +0.3%
BCA
1194
Bay Colony Advisors
Massachusetts
$1.66M -$132K -4,530 -7%
WB
1195
Webster Bank
Connecticut
$1.66M -$177K -6,081 -10%
CCG
1196
Ceeto Capital Group
Florida
$1.66M +$14.6K +500 +0.9%
BIAS
1197
Beacon Investment Advisory Services
New Jersey
$1.65M -$1.11M -38,130 -40%
PCM
1198
Prelude Capital Management
New York
$1.65M +$42.2K +1,447 +3%
CAM
1199
Costello Asset Management
Pennsylvania
$1.65M +$1.37M +46,795 +462%
LA
1200
Legacy Advisors
Pennsylvania
$1.64M +$148K +5,071 +10%

PFE Hedge Fund Activity: Q3 2024 in Review

2,910 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2024, worth a combined $109B — up 3.7% from $105B a quarter earlier.

Buyers outnumbered sellers: 191 funds opened new PFE positions and 124 closed out — a net gain of 67 holders — while 1,243 added to existing stakes and 1,199 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $425M. The largest seller was Capital World Investors, cutting an estimated $1.01B.

  • 2,910 institutional investors held Pfizer (PFE) as of Q3 2024, up from 2,874 in Q2 2024.
  • Funds reported $109B of Pfizer stock for Q3 2024, up 3.7% quarter-over-quarter.
  • 191 funds opened new Pfizer positions in Q3 2024 and 124 closed out, a net change of +67 holders.
  • The largest Pfizer buyer in Q3 2024 was BNP Paribas Financial Markets, an estimated $425M added.
  • The largest Pfizer seller in Q3 2024 was Capital World Investors, an estimated $1.01B sold.

Based on aggregated 13F filings for Q3 2024.